Multiple Myeloma — Trials

Multiple Myeloma — Trials · CancerIndex

Clinical trials

Registered studies

3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 814
Recruiting: 414
Ph III recruiting: 54
Growth YoY: +13.3%
Industry share: 29%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.1%
Trials / 1,000 deaths: 70.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (537)

clinicaltrialsPublishedShowing 1–50 of 82 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05874193	A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma(COSTA)	withdrawn	Phase 2	0	Cristiana Costa Chase, DOOTHER	1	Sep 28, 2026	clinicaltrials
NCT07428369	A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)(LINKER-MM8)	withdrawn	Phase 2 / Phase 3	0	Regeneron PharmaceuticalsINDUSTRY	0